Can autoantibody tests enhance lung cancer screening?—an evaluation of EarlyCDT®-Lung in context of the German Lung Cancer Screening Intervention Trial (LUSI)
Autor: | Erna Motsch, Sandra González Maldonado, Rudolf Kaaks, Stefan Delorme, Theron Johnson |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Lung business.industry Autoantibody Cancer Context (language use) medicine.disease 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure 030228 respiratory system Oncology 030220 oncology & carcinogenesis Internal medicine Medicine Stage (cooking) business Lung cancer Lung cancer screening Test panel |
Zdroj: | Translational Lung Cancer Research. 10:233-242 |
ISSN: | 2226-4477 2218-6751 |
Popis: | Background Tumor-associated autoantibodies are considered promising markers for early lung cancer detection; so far, however, their capacity to detect cancer has been tested mostly in a clinical context, but not in population screening settings. This study evaluates the early detection accuracy, in terms of sensitivity and specificity, of EarlyCDT®-Lung-a test panel of seven tumor-associated autoantibodies optimized for lung cancer detection-using blood samples originally collected as part of the German Lung Cancer Screening Intervention Trial. Methods The EarlyCDT®-Lung test was performed for all participants with lung cancer detected via low-dose computed tomography and with available blood samples taken at detection, and for 180 retrospectively selected cancer-free participants at the end of follow-up: 90 randomly selected from among all cancer-free participants (baseline controls) and 90 randomly selected from among cancer-free participants with suspicious imaging findings (suspicious nodules controls). Sensitivity and specificity of lung cancer detection were estimated in the case group and the two control groups, respectively. Results In the case group, the test panel showed a sensitivity of only 13.0% (95% CI: 4.9-26.3%). Specificity was estimated at 88.9% (95% CI: 80.5-94.5%) in the baseline control group, and 91.1% (95% CI: 83.2-96.1%) among controls presenting CT-detected nodules. Conclusions The test panel showed insufficient sensitivity for detecting lung cancer at an equally early stage as with low-dose computed tomography screening. |
Databáze: | OpenAIRE |
Externí odkaz: |